Company Overview
Profusa, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry where it develops bioengineered sensors designed to detect and continuously transmit clinical-grade data for personal and medical applications in the United States. The company's core product offering, the Lumee Oxygen Platform, is engineered to monitor compromised tissue, addressing critical needs in the treatment of peripheral artery disease, chronic wounds, and reconstructive surgery. Regarding its scale, the company carries a market capitalization of $645,158, while its annual revenue and employee count are not disclosed in the available data. This market cap figure indicates a micro-cap status, suggesting that the company operates with a very limited public float and likely lacks the extensive resources of larger peers in the medical device sector. The absence of reported revenue and employee data further contextualizes the company's position as a small entity where traditional scale metrics have not yet been materialized or reported to public standards.
Financial Health
The company's financial statements reveal a significant gap between revenue and profitability, with reported revenue of N/A, a net income of $-29,508,000, and an EBITDA of N/A. The absence of reported revenue figures combined with a substantial net loss indicates that the company is in a pre-revenue or early-stage loss position where operating costs and research expenses significantly outweigh any current income generation. The free cash flow stands at $-10,704,875, which reflects a heavy burn rate and limited financial flexibility to fund operations or capital expenditures without external financing. All three margin metrics—gross margin, operating margin, and profit margin—are reported as 0.0%, indicating that the company has not yet achieved profitability or that the data does not support a calculation of positive margins at this stage. The balance sheet presents a leveraged profile, holding $3.01M in cash against $21.07M in debt, resulting in a debt-to-equity ratio that is not calculable due to the negative equity situation. This disparity between cash and debt suggests the company relies on borrowing to sustain operations while seeking to generate positive cash flows. Liquidity is constrained further by a current ratio of 0.18, which indicates that the company's current assets are insufficient to cover its current liabilities, signaling potential short-term solvency challenges. Return on Equity and Return on Assets metrics are unavailable or indicate severe underperformance, with ROA at -465.1%, revealing that management has not yet been effective in generating returns on the capital base provided by shareholders.
Valuation Assessment
The trailing P/E ratio and forward P/E ratio are both reported as N/A, which implies that earnings are currently negative and traditional earnings-based valuation multiples cannot be applied to assess the company's expected earnings trajectory. The price-to-book ratio is listed at -0.01, a figure that indicates the market values the company at a negligible amount relative to its book value, often reflecting investor skepticism about the recoverability of the company's assets or its path to profitability. Alternative valuation metrics such as the price-to-sales ratio are reported as inf, and the EV/EBITDA is N/A, suggesting that revenue-based or enterprise value-based comparisons to peers are not feasible given the lack of positive earnings or standard revenue reporting. The 52-week high is $412.50 and the 52-week low is $0.41, meaning the current trading price sits significantly below the 52-week high and only slightly above the 52-week low, highlighting extreme volatility and a wide trading range. The beta value is -0.01, a negative figure that implies the stock's price movements are inversely correlated with the broader market or that the calculation is based on historical data that does not reflect current volatility expectations for a company with such a low market cap.
Growth & Income
Revenue growth and earnings growth rates are reported as N/A, indicating that there is no historical data available to determine whether earnings are growing faster or slower than revenue or if the company has a consistent growth trajectory. Since the company does not pay a dividend, the dividend yield and payout ratio are both N/A and 0.0% respectively, meaning the company reinvests its limited earnings or capital into growth initiatives rather than distributing cash to shareholders. The overall growth and income profile is characterized by a lack of historical growth data and an absence of dividend income, relying entirely on future operational success to generate value for investors. This profile suggests that the company's value proposition is entirely dependent on future revenue generation and operational turnaround rather than current income or established growth rates.